Literature DB >> 16846800

Modulating TNF-alpha signaling with natural products.

Atish T Paul1, Vikrantsinh M Gohil, Kamlesh K Bhutani.   

Abstract

Natural products have been, and continue to be, a major source of pharmacologically active substances from which drugs can be developed. Currently, tumor necrosis factor-alpha (TNF-alpha) inhibitors from natural origins are being advanced for the treatment of inflammatory disorders. Elevated TNF-alpha synthesis has been associated with the development of diabetes, septic shock, tumorigenesis, rheumatoid arthritis, psoriatic arthritis and inflammatory bowel disease. Currently, only protein-based drugs are available for the clinical inhibition of TNF-alpha activity. Small-molecule drugs that can regulate TNF-alpha levels or activity might provide a cost-effective alternative to protein-based therapeutics. This review briefly highlights the physiological and pathological roles of TNF-alpha, and covers those natural compounds capable of interfering with TNF-alpha activity.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16846800     DOI： 10.1016/j.drudis.2006.06.002

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  25 in total

Review 1.  Current status and challenges of cytokine pharmacology.

Authors:  Z Zídek; P Anzenbacher; E Kmonícková
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

Review 2.  Recent advances in cytokines: therapeutic implications for inflammatory bowel diseases.

Authors:  Guillaume Bouguen; Jean-Baptiste Chevaux; Laurent Peyrin-Biroulet
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

Review 3.  Immunogenetic biomarkers in inflammatory bowel diseases: role of the IBD3 region.

Authors:  Manuel Muro; Ruth López-Hernández; Anna Mrowiec
Journal:  World J Gastroenterol       Date:  2014-11-07       Impact factor: 5.742

4.  Combination treatment with oxaliplatin and mangiferin causes increased apoptosis and downregulation of NFκB in cancer cell lines.

Authors:  D du Plessis-Stoman; Jgh du Preez; M van de Venter
Journal:  Afr J Tradit Complement Altern Med       Date:  2010-12-30

5.  Differential chemosensitization of P-glycoprotein overexpressing K562/Adr cells by withaferin A and Siamois polyphenols.

Authors:  Wipob Suttana; Samlee Mankhetkorn; Wilart Poompimon; Ajay Palagani; Sergey Zhokhov; Sarah Gerlo; Guy Haegeman; Wim Vanden Berghe
Journal:  Mol Cancer       Date:  2010-05-03       Impact factor: 27.401

6.  Two additive mechanisms impair the differentiation of 'substrate-selective' p38 inhibitors from classical p38 inhibitors in vitro.

Authors:  Bart S Hendriks; Kelly M Seidl; Jeffrey R Chabot
Journal:  BMC Syst Biol       Date:  2010-03-15

7.  A synthetic peptide derived from A1 module in CRD4 of human TNF receptor-1 inhibits binding and proinflammatory effect of human TNF-alpha.

Authors:  Yingnan Cao; Zhaohe Wang; Xianzhang Bu; Shu Tang; Zhengrong Mei; Peiqing Liu
Journal:  Inflammation       Date:  2009-06       Impact factor: 4.092

8.  Synthesis of tumor necrosis factor α for use as a mirror-image phage display target.

Authors:  Mark E Petersen; Michael T Jacobsen; Michael S Kay
Journal:  Org Biomol Chem       Date:  2016-05-23       Impact factor: 3.876

9.  Two New 3,4;9,10-seco-Cycloartane Type Triterpenoids from Illicium difengpi and Their Anti-Inflammatory Activities.

Authors:  Chuntong Li; Fengmin Xi; Junling Mi; Zhijun Wu; Wansheng Chen
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-15       Impact factor: 2.629

10.  Soybean glyceollins mitigate inducible nitric oxide synthase and cyclooxygenase-2 expression levels via suppression of the NF-κB signaling pathway in RAW 264.7 cells.

Authors:  Eun-Kyung Yoon; Hyun-Kyoung Kim; Song Cui; Yong-Hoon Kim; Sang-Han Lee
Journal:  Int J Mol Med       Date:  2012-01-12       Impact factor: 4.101
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.